Quale sarebbe il prezzo per Metagenomi, Inc. Common Stock (MGX)

Il prezzo per Metagenomi, Inc. Common Stock (MGX) è $1.21

Qual è la capitalizzazione di mercato per Metagenomi, Inc. Common Stock (MGX)

La capitalizzazione di mercato per Metagenomi, Inc. Common Stock (MGX) è $45.55M

Metagenomi, Inc. Common Stock (MGX) Prezzo e Capitalizzazione di Mercato

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Il prezzo per MGX	Attivo B	Capitalizzazione del mercato a B	Risultati
$139,635 $45.55M	NVDA	$5.257T	+11,540,904.48%
$122,151 $45.55M	AAPL	$4.599T	+10,095,879.35%
$109,081 $45.55M	GOOG	$4.107T	+9,015,580.80%
$95,020.45 $45.55M	MSFT	$3.577T	+7,853,478.82%
$74,568.78 $45.55M	AMZN	$2.807T	+6,163,118.37%

Il prezzo per MGX

Attivo B

Capitalizzazione del mercato a B

Risultati

$139,635 $45.55M